Results from the first-in-human phase 1 study of LY4170156, a folate receptor alpha-targeting antibody drug conjugate, in ovarian cancer patients previously exposed to antibody drug conjugate therapy

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Ainhoa Madariaga, Ana Oaknin, Chrisann Kyi, Bhavana Pothuri, Nehal J. Lakhani, Takafumi Koyama, Shigehisa Kitano, William Bennion McKean, Meena Okera, Myong Cheol Lim, Alejandro Perez-Fidalgo, Giuseppe Curigliano
+8 more Domenica Lorusso, Ramez N. Eskander, Shannon N. Westin, Chunxiao C. Wang, Marina Manvelyan, Emin Avşar, David M. O'Malley, Isabelle Ray-Coquard
DOI: 10.1016/j.ijgc.2025.102906
Cited by: 2

Fields of Study & Subjects

HER2/EGFR in Cancer Research Ovarian cancer diagnosis and treatment Growth Hormone and Insulin-like Growth Factors

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
2
Pages
102906–102906
Publication date
1 February 2026
Language
EN